Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease

NCT00749216 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: Solanezumab

Sponsor

Eli Lilly and Company